Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy compared with lactulose monotherapy ...

Bajaj JS, et al. Rifaximin monotherapy is more effective than lactulose monotherapy for reducing the risk of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality: An analysis of ...

For patients with overt hepatic encephalopathy, rifaximin monotherapy results in significantly fewer OHE episodes than lactulose MT.

News Release 25-Jun-2025 Long-term use of rifaximin in cirrhotic patients with hepatic encephalopathy Peer-Reviewed Publication Xia & He Publishing Inc.

New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC ...

With hepatic encephalopathy, certain bacteria produce ammonia that gets into your brain and causes symptoms. Xifaxan works by killing ammonia-producing bacteria.

Xifaxan is a prescription drug used to treat traveler’s diarrhea, hepatic encephalopathy, and IBS diarrhea. Learn about its dosages, form, strengths, and more.

This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE ...

For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer OHE episodes than lactulose (LAC) MT, according to a study presented at ...

"Rifaximin is very expensive, but so is an unnecessary hospitalization for hepatic encephalopathy that can sometimes result in an ICU stay," he noted.

XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults and for the treatment of irritable bowel syndrome with ...